Cp55 940

CP55940, WIN55212‐2, 2‐arachidonoylglycerol (2‐AG), CUMYL‐4CN‐BINACA, and SR141716A were purchased from Cayman Chemical, THC was from THC Pharm GmbH and was a kind gift from the Lambert Initiative for Cannabis Therapeutics (University of Sydney). PTX was from HelloBio, and FSK was from Ascent Scientific Ltd. All the SCRAs, unless otherwise stated, were synthesized by Dr Samuel D. Banister in the lab of Professor Michael Kassiou at Sydney University. Chemical structure of SCRAs can be found elsewhere.12 All the SCRAs were prepared in DMSO and stored in aliquots of 30 mmol L⁻¹ in −30°C until needed.

Oligonucleotides were purchased from Operon Biosciences. Restriction enzymes and DNA-modifying enzymes were obtained from New England Biolabs. The Ni-NTA resin was from Qiagen. The StrepTactin XT Superflow was IBA GmbH. Mouse monoclonal antibodies against 6x-His tag were from ThermoFisher Scientific (Cat No MA1-21315). Mouse monoclonal antibody against GFP were from Invitrogen (Cat No GF28R, MA5-15256). Monoclonal antibody against human cannabinoid receptor CB₂ was from R&D Systems (Cat No MAB36551-10 or FAB36551R). Mouse monoclonal antibody against Streptag were from IBA Life Sciences (Cat No 2-1507-001). Secondary ECL anti-mouse IgG from sheep conjugated with horseradish peroxidase were from GE Healthcare (Cat No NA931). Cholesteryl hemisuccinate Tris salt (CHS) and detergents 3 [(cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS) and n-dodecyl-β-d-maltoside (DDM) were obtained from Anatrace. Façade-TEG detergent was purchased from Avanti Polar Lipids Inc. Synthetic cannabinoid ligand CP-55,940 was from Cayman (Cat No 90084). ¹³C₅-methionine was from Cambridge Isotopes (Cat No CLM-893-H-MPT-PK).
Expi293F cells (Cat No A14635) and Expi293F GNTI⁻ cells (A39240), expression media and transfection kits (Cat No A14635), and the Methionine labeling kit (Cat No A41249) were from ThermoFisher Scientific.
All other chemicals of reagent grade were purchased from Sigma.

AM251, SR141716A (Rimonabant), URB447, LH21, AM630, O-2545, and CP55,940 were obtained from Cayman Chemical (Ann Arbor, MI) and Gp1a was obtained from Tocris Bioscience (Minneapolis, MN).

WIN55,212-2 and BAY59-3074 (BAY) were purchased from Tocris Bioscience (Bristol, United Kingdom). CP55,940, AEA, 2-AG, JWH-015, and JWH-133 were purchased from Cayman Chemical Company (Ann Arbour, MI, United States). (-)-trans-THC was purchased from THC Pharm GmbH (Frankfurt, Germany). Dopamine hydrochloride was purchased from Sigma–Aldrich (St. Louis, MO, United States). Arginine vasopressin (AVP) was a kind gift from Dr. Mark Oliver (The University of Auckland, Auckland, New Zealand).
Drug stocks were prepared in absolute ethanol (CP55,940, WIN55,212-2, AEA, 2-AG, THC, BAY, JWH-133) or DMSO (JWH-015) and were stored in aliquots at -80°C prior to use. Dopamine and AVP were made up in H₂O immediately prior to use. Drug aliquots used for experiments involving serial dilutions were always single-use. Vehicle controls for serial dilutions were maintained constant within experiments.

Δ⁹-THC was obtained from THCPharm (Frankfurt, Germany). Terpenoids were obtained from Sigma-Aldrich; (+)-α-pinene, (+)-β-pinene, (−)-β-caryophyllene, (+/−)-linalool, (R)-(+)-limonene, and β-myrcene. SST was obtained from Auspep and CP55,940 from Cayman. Unless otherwise indicated, the other chemicals and reagents were obtained from Sigma-Aldrich.